Lumiio

Lumiio Lumiio specializes in real-world data collection services that drive health outcomes. Formerly Dataffinity Health.

Introducing the new MyMito 🎉 The new MyMito app is here, rebuilt in partnership with MitoAction and the mito community o...
11/09/2026

Introducing the new MyMito 🎉

The new MyMito app is here, rebuilt in partnership with MitoAction and the mito community of patients, families, and caregivers who helped shape it.

MyMito has been the go-to health companion for the mitochondrial disease community. Now it’s powered by Lumiio’s modernized health community platform, purpose-built to reflect the realities of life with mitochondrial disease.

Patients and caregivers shouldn’t have to piece together their health story across a dozen different apps, notebooks, and spreadsheets. MyMito brings everything together into a centralized mito hub - tracking, insights, journaling, care information, and more - so the focus stays on living well with mito.

And this is just the beginning. New features are rolling out based on what the community tells us matters most, because MyMito is a partnership, and it’s evolving with you.

Thank you to our partners at MitoAction for trusting us to help build their vision.

Built for mito. Shaped by you. Powered by Lumiio.

👉 Living with mito? Download MyMito on the App Store or Google Play using the link in the comments
👉 Leading a patient community in another disease area? We’d love to talk about launching in yours. Reach out to us at [email protected]

hashtag hashtag hashtag hashtag hashtag hashtag hashtag

Something new is coming for the ALS community, and it’s been shaped by the people who know it best. We're putting the fi...
11/05/2026

Something new is coming for the ALS community, and it’s been shaped by the people who know it best.

We're putting the final touches on a new app designed around the experiences and needs of people living with ALS and those who support them. It’s a cause close to the heart of our Head of Patient Experience & Product, Grace Westbury, who has championed this work from the first concept to the version we’re getting ready to share.

More than 140 people across Canada helped shape it – people living with ALS, family members, clinicians, care providers, and researchers. Across multiple rounds of prototypes, their feedback made the calls that mattered: what stayed, what changed, and what ultimately got built. The result is an app shaped around real needs instead of assumptions.

We can’t wait to see it in people’s hands soon. And there's more to come for the ALS community and beyond. Stay tuned! 💜

10 years of Lumiio. One clear mission.In 2016, we started with an idea: the experience of people living with a condition...
10/27/2026

10 years of Lumiio. One clear mission.

In 2016, we started with an idea: the experience of people living with a condition was evidence worth capturing.

That idea became a platform. Then a community. Then many communities. From rare diseases to complex conditions, we’ve spent a decade building the tools and partnerships that turn patient voices into real-world evidence and impact.

Our technology, our scale, the diseases we serve and the organizations we partner with have all evolved. We’ve gone from an idea to a global platform powering health communities across 70+ countries.

But the mission has never moved. Advance health outcomes by capturing, connecting, and amplifying the patient experience. That was our purpose on day one. It remains our purpose today.

What’s changed is our ability to deliver on it and the momentum behind us as we head into the next chapter.

A heartfelt thank you to the patients and families who share their stories so that others don’t have to start from scratch. To the patient organizations, researchers, advocates, and partners who’ve trusted us with their communities, and who believe, like we do, that people living with a condition know things the health system can’t afford to miss. And to the team, past and present, who helped make it all possible.

Here’s to our first decade. We’re just getting started. 🚀

🌍 70+ countries. One incredibly rare disease. One global mission to advance research.Today, we’re excited to highlight a...
10/21/2026

🌍 70+ countries. One incredibly rare disease. One global mission to advance research.

Today, we’re excited to highlight a major milestone: The International FOP Association (IFOPA) is now leveraging Lumiio’s platform to power its global Registry program, spanning more than 70 countries worldwide!

Fibrodysplasia Ossificans Progressiva (FOP) affects approximately 1 in one million people, making it one of the rarest diseases in the world.

When a disease is this rare, every patient experience matters.

Over the years, IFOPA has built an extraordinary global community dedicated to advancing research, improving care, and ensuring the voices of people living with FOP are heard. Now, we’re proud to support the next chapter of that mission.

By leveraging Lumiio’s platform, IFOPA can capture patient experiences over time, generate meaningful insights, and strengthen its ability to advance research and improve care for people living with FOP.

This is about more than technology. It’s about empowering patient organizations with the tools to turn lived experiences into meaningful research.

We’re incredibly proud to partner with IFOPA and excited to see the impact this program will continue to make around the world. 💙

🚀 We’ve been busy, and there’s a lot more to come! Reach out to learn more about how we partner with rare disease communities to build tools that make a difference.

What an incredible weekend for the PANS/PANDAS community! 🎉On Saturday, September 19th, the  Brain Alliance hosted their...
09/21/2026

What an incredible weekend for the PANS/PANDAS community! 🎉

On Saturday, September 19th, the Brain Alliance hosted their Steppin' Out for PANS/PANDAS Walk and the energy was something special - Beautiful weather, an amazing turnout, and a community showing up in full force.

As proud partners of the Inflamed Brain Alliance, it was amazing to see the community rally together. Dr. Metz, MLA and neurologist, spoke as a special guest and drove home a message that resonates deeply with us at Lumiio: data and evidence are essential to advancing advocacy and improving standards of care.

Our CEO Penny also took the stage with a complementary message - that the collective voice of a community is powerful, and when patients and families come together, real change follows.

The momentum is real. IBA's patient registry is growing rapidly and the community blew past their $50,000 fundraising goal, raising over $62,000 and counting.

This is what patient-powered advocacy looks like. đź’›

Most AI systems treat governance as a compliance exercise. Something you document, tick off, and move on from. We're bui...
04/15/2026

Most AI systems treat governance as a compliance exercise. Something you document, tick off, and move on from.

We're building things differently.

At Lumiio, governance, transparency, and patient agency are not boxes to check, they are design requirements. Because in rare disease, where communities are small, trust is hard won, and participation is everything, an AI system that does not put patients at the centre will not work. Not ethically, and not practically.

Mel Hayes and Dr. Lawrence Korngut from our team have written about exactly this. What patient-governed AI actually looks like. Why trust is the infrastructure, not a feature. And what it means to build a system where patients are genuine partners in how their data is used.

If you work in rare disease, health AI, or patient advocacy, this one is worth your time.

Read it here: https://www.lumiio.com/news-research/patient-governed-ai-the-trust-infrastructure-rare-disease-will-need-next/

International FOP Association (IFOPA) Inflamed Brain Alliance MitoCanada FSHD Society

By Mel Hayes and Dr. Lawrence Korngut. With contributions from Victoria Hodgkinson, PhD, Blaine Penny, and Ken Kahtava. What This Article Argues In rare disease, the biggest risk in AI is not that it will have a lack of data to provide insights — it is whether those insights can be trusted. As AI ...

Today is  . 🦓300 million people worldwide live with a  . Yet for most of them, the journey to diagnosis takes years, som...
02/28/2026

Today is . 🦓

300 million people worldwide live with a . Yet for most of them, the journey to diagnosis takes years, sometimes decades. And for many, a treatment never comes.

We want to pause and recognize the organizations that refuse to accept that reality - the patient advocacy groups, rare disease foundations, researchers, and caregivers who show up every single day for communities that are too often invisible to the broader healthcare system. You are the reason progress happens.

At Lumiio, we believe that rare shouldn't mean forgotten, and we believe technology, data, AI and community have a real role to play in changing that. From cutting through diagnostic odysseys to connecting patients with the right support faster than ever before, the potential is enormous, but so is the responsibility to get it right.

So we want to hear from you:

👉 Where do you think AI could make the biggest near-term difference in rare diseases - shortening time to diagnosis, improving care coordination, accelerating research and clinical trials, or expanding patient support - and why?

Drop your thoughts in the comments. Every perspective matters, and it's exactly what drives us.

Inflamed Brain Alliance MitoCanada ALS Canada FSHD Society International FOP Association (IFOPA)

Address

Calgary, AB

Opening Hours

Monday 8am - 6pm
Tuesday 8am - 6pm
Wednesday 8am - 6pm
Thursday 8am - 6pm
Friday 8am - 6pm

Alerts

Be the first to know and let us send you an email when Lumiio posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share